Transplantation

Journal

Publication Venue For

  • Early Outcomes With the Liver-kidney Safety Net.  105:1261-1272. 2021
  • Prediction of Organ Donation After Circulatory Death: In Search of a Better Crystal Ball.  105:1165-1166. 2021
  • What Therapeutic Regimen Will Be Optimal for Initial Clinical Trials of Pig Organ Transplantation?.  105:1143-1155. 2021
  • B Cells Break Maternal T-Cell Tolerance of Fetal Antigen.  1637-1638. 2021
  • Cardiac Mortality following Kidney Transplantation: Progress Made but Still Room for Improvement.  278-279. 2021
  • Center-level Variation in HLA-incompatible Living Donor Kidney Transplantation Outcomes.  436-442. 2021
  • Early Kidney Allograft Failure after Simultaneous Liver-kidney Transplantation: Evidence for Utilization of the Safety Net?.  816-823. 2021
  • Suggested Patient Selection Criteria for Initial Clinical Trials of Pig Kidney Xenotransplantation in the United States.  1904-1908. 2021
  • Thirty Years of Tacrolimus in Clinical Practice.  484-495. 2021
  • A Video Intervention to Increase Organ Donor Registration at the Department of Motorized Vehicles.  104:788-794. 2020
  • Enhanced Advocacy and Health Systems Training through Patient Navigation Increases Access to Living-donor Kidney Transplantation.  122-129. 2020
  • Geographic differences in population health and expected organ supply in the Gulf Coast Region of the United States compared to non-Gulf States.  421-427. 2020
  • Global transplantation COVID report march 2020.  1974-1983. 2020
  • Impact of Donor Hepatitis C Virus on Kidney Transplant Outcomes for Hepatitis C-positive Recipients in the Direct-acting Antiviral Era: Time to Revise the Kidney Donor Risk Index?.  1215-1228. 2020
  • Late Graft Loss after Kidney Transplantation: Is "death with Function" Really Death with a Functioning Allograft?.  1483-1490. 2020
  • Social determinants of health: Going beyond the basics to explore racial disparities in kidney transplantation.  1324-1325. 2020
  • Life-supporting Kidney Xenotransplantation from Genetically Engineered Pigs in Baboons: A Comparison of Two Immunosuppressive Regimens.  103:2090-2104. 2019
  • Center variation and risk factors for failure to complete 6 month postdonation follow-up among obese living kidney donors.  103:1450-1456. 2019
  • Ethnic and age disparities in outcomes among liver transplant waitlist candidates.  103:1425-1432. 2019
  • Establishing a core outcome measure for life participation: A standardized outcomes in nephrology-kidney transplantation consensus workshop report.  103:1199-1205. 2019
  • Population Health, Ethnicity, and Rate of Living Donor Kidney Transplantation.  102:2080-2087. 2018
  • Intraoperative Management of Liver Transplant Patients Without the Routine Use of Renal Replacement Therapy.  102:e229-e235. 2018
  • Long Cold Ischemia Times in Same Hospital Deceased Donor Transplants.  102:471-477. 2018
  • Patient and Kidney Allograft Survival in Recipients with End-Stage Renal Disease from Amyloidosis.  102:300-309. 2018
  • Living Kidney Donor Phenotype and Likelihood of Postdonation Follow-up.  102:135-139. 2018
  • A Difficult Decision: Atypical JC Polyomavirus Encephalopathy in a Kidney Transplant Recipient..  101:1461-1467. 2017
  • Cost-effectiveness of antibody-based induction therapy in deceased donor kidney transplantation in the United States.  101:1234-1241. 2017
  • Long-Term Renal Function in Living Kidney Donors Who Had Histological Abnormalities at Donation.  100:1294-1298. 2016
  • APOL1 genotype and kidney transplantation outcomes from deceased african American donors.  100:194-202. 2016
  • Long-Term outcomes after liver transplantation among human immunodeficiency virus-infected recipients.  100:141-146. 2016
  • The kidney-vascular-bone axis in the chronic kidney disease-mineral bone disorder.  100:497-505. 2016
  • Choosing the order of deceased donor and living donor kidney transplantation in pediatric recipients: A Markov decision process model.  99:360-366. 2015
  • Center-level variation in the development of delayed graft function after deceased donor kidney transplantation.  99:997-1002. 2015
  • Frailty, mycophenolate reduction, and graft loss in kidney transplant recipients.  99:805-810. 2015
  • Islet size index as a predictor of outcomes in clinical islet autotransplantation.  97:1286-1291. 2014
  • The authors' reply.  97. 2014
  • Resource utilization associated with procurement of transplantable organs from donors that do not meet OPTN eligible death criteria.  97:1043-1048. 2014
  • Impact of immunosuppression on recall immune responses to influenza vaccination in stable renal transplant recipients.  97:846-853. 2014
  • Immunosuppression regimen and the risk of acute rejection in HIV-infected kidney transplant recipients.  97:446-450. 2014
  • Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation.  98:857-863. 2014
  • Order of donor type in pediatric kidney transplant recipients requiring retransplantation.  96:487-493. 2013
  • Hepatitis C virus infection in heart transplantation: Is ventricular assist device therapy an option?.  96. 2013
  • Outcomes in systemic sclerosis-related lung disease after lung transplantation.  95:975-980. 2013
  • Erratum: Is decedent race an independent predictor of organ donor consent or merely a surrogate marker of socioeconomic status (Transplantation (2012) 2:94 (873)).  95. 2013
  • Ganciclovir prophylaxis improves late murine cytomegalovirus-induced renal allograft damage.  95:48-53. 2013
  • Is decedent race an independent predictor of organ donor consent or merely a surrogate marker of socioeconomic status?.  94:873-878. 2012
  • Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients.  93:1075-1085. 2012
  • Reply to "genetic determinants of mycophenolate-related anemia and leukopenia after transplantation".  93. 2012
  • Total lymphoid irradiation in heart transplantation: Long-term efficacy and survival-an 18-year experience.  92:1159-1164. 2011
  • African American living-kidney donors should be screened for apol1 risk alleles.  92:722-725. 2011
  • Ganciclovir transiently attenuates murine cytomegalovirus-associated renal allograft inflammation.  92:759-766. 2011
  • Gene polymorphisms impact the risk of rejection with hemodynamic compromise: A multicenter study.  91:1326-1332. 2011
  • Genetic determinants of mycophenolate-related anemia and leukopenia after transplantation.  91:309-316. 2011
  • Novel polymorphisms associated with tacrolimus trough concentrations: Results from a multicenter kidney transplant consortium.  91:300-308. 2011
  • Optimal cutoff point for immunoperoxidase detection of C4d in the renal allograft: Results from a multicenter study.  90:1099-1105. 2010
  • Evidence for antibody-mediated injury as a Major determinant of late kidney allograft failure.  90:68-74. 2010
  • Genotypic variation and phenotypic characterization of granzyme B gene polymorphisms.  87:1801-1806. 2009
  • ABO incompatible renal transplantation: A paradigm ready for broad implementation.  87:1246-1255. 2009
  • Adenovirus infection activates akt1 and induces cell proliferation in pancreatic islets1.  87:821-824. 2009
  • Erratum: Peritransplant tolerance induction in macaques: Early events reflecting the unique synergy between immunotoxin and deoxyspergualin (Transplantation (1999) 68:11 (1660-1673)).  86:482. 2008
  • Erratum: Tolerability and side effects of anti-CD3-immunotoxin in preclinical testing in kidney and pancreatic islet transplant recipients (Transplantation (1999) 68:2 (215-219)).  86:482. 2008
  • Genetic polymorphisms impact the risk of acute rejection in pediatric heart transplantation: A multi-institutional study.  85:1632-1639. 2008
  • Declining outcomes in simultaneous liver-kidney transplantation in the MELD era: Ineffective usage of renal allografts.  85:935-942. 2008
  • Retraction: Peritransplant tolerance induction with anti-CD3-immunotoxin: A matter of proinflammatory cytokine control (Transplantation (1998) 65, 9, (1159-1169)).  85:920. 2008
  • ABO-incompatible transplantation: Less may be more.  84. 2007
  • The impact of left ventricular systolic dysfunction on survival after renal transplantation.  84:1610-1617. 2007
  • Is xenotransplantation of embryonic stem cells a realistic option?.  83:333-335. 2007
  • Factors affecting graft survival after liver transplantation from donation after cardiac death donors.  82:1683-1688. 2006
  • Liver and kidney transplantation for polycystic liver and kidney-renal function and outcome.  82:501-507. 2006
  • Posttransplant lymphoproliferative disorder among renal transplant patients in relation to the use of mycophenolate mofetil.  80:1174-1180. 2005
  • Mycophenolate mofetil: Ten years of clinical experience. Introduction.  80. 2005
  • Can cold or heat shock improve skeletal myoblast engraftment in infarcted myocardium?.  80:660-665. 2005
  • Cadaveric orthotopic auxiliary split liver transplantation and kidney transplantation: An alternative for type 1 primary hyperoxaluria.  80:421-424. 2005
  • United Network for Organ Sharing publication on scientific registry of transplant recipients central nervous system donor cancer transmission data [4].  79:623. 2005
  • Inhibition of cellular immune responses to encapsulated porcine islet xenografts by simultaneous blockade of two different costimulatory pathways.  79:409-418. 2005
  • Experience with 274 cardiac transplant recipients with posttransplant lymphoproliferative disorder: A report from the Israel penn international transplant tumor registry.  78:1676-1682. 2004
  • Two-dose daclizumab induction therapy in 209 liver transplants: A single-center analysis.  78:1212-1217. 2004
  • Recurrence risk after organ transplantation in patients with a history of Hodgkin disease or non-Hodgkin lymphoma.  78:972-977. 2004
  • Leflunomide therapy for cytomegalovirus disease in renal allograft recepients.  77:1460-1461. 2004
  • Right donor nephrectomy: A comparison of hand-assisted transperitoneal and retroperitoneal laparoscopic approaches.  77:521-525. 2004
  • West Nile virus encephalitis in organ transplant recipients: Another high-risk group for meningoencephalitis and death?.  77:466-469. 2004
  • The changing clinical presentation of recurrent primary biliary cirrhosis after liver transplantation.  76:1583-1588. 2003
  • Graft protective effects of heme oxygenase 1 in mouse tracheal transplant-related obliterative bronchiolitis.  76:650-656. 2003
  • Donors with central nervous system malignancies: Are they truly safe?.  76:340-343. 2003
  • Allogeneic bone marrow inhibits T-cell activation and clonal expansion in vitro.  76:237-243. 2003
  • Double genetic modification of adenovirus fiber with RGD polylysine motifs significantly enhances gene transfer to isoiated human pancreatic islets.  76:252-261. 2003
  • MALToma: A Helicobacter pylori-associated malignancy in transplant patients: A report from the Israel Penn International Transplant Tumor Registry with a review of published literature.  75:225-228. 2003
  • Bone mineral density changes within six months of renal transplantation.  75:49-54. 2003
  • Bone mineral density changes within six months of renal transplantation..  75:49-54. 2003
  • Liver transplant-associated graft-versus-host disease.  75:118-126. 2003
  • Maximizing renal artery length in right laparoscopic donor nephrectomy by retrocaval exposure of the aortorenal junction.  75:83-85. 2003
  • 17β-estradiol protects isolated human pancreatic islets against proinflammatory cytokine-induced cell death: Molecular mechanisms and islet functionality.  74:1252-1259. 2002
  • Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders.  74:1090-1095. 2002
  • Simvastatin induces activation of the serine-threonine protein kinase Akt and increases survival of isolated human pancreatic islets.  74:1063-1069. 2002
  • The nondirected live-kidney donor: Ethical considerations and practice guidelines. A national conference report.  74:582-589. 2002
  • Chlamydia pneumoniae respiratory infection after allogeneic stem cell transplantation.  73:1002-1005. 2002
  • An essential role for natural killer cells in augmentation of allograft survival mediated by donor spleen cells.  72:954-956. 2001
  • Results of a randomized, prospective, multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection.  71:1772-1776. 2001
  • Tolerance in renal transplantation after allogeneic bone marrow transplantation-6-year follow-up.  71:1681-1683. 2001
  • The role of anti-Galα1-3Gal antibodies in acute vascular rejection and accommodation of xenografts.  70:1667-1674. 2000
  • A differential requirement for CD8+ donor cells in the augmentation of allograft survival by posttransplantation administration of donor spleen cells and donor bone marrow cells.  70:1068-1073. 2000
  • Long-term results of liver transplantation in patients 60 years of age and older.  70:780-783. 2000
  • Opening of mitochondrial potassium channels: A new target for graft preservation strategies?.  70:576-578. 2000
  • Significance of blood stream infection after lung transplantation: Analysis in 176 consecutive patients.  69:2360-2366. 2000
  • The safety and efficacy of a two-dose daclizumab (Zenapax) induction therapy in liver transplant recipients.  69:1867-1872. 2000
  • Enhanced allograft survival induced by posttransplant donor spleen cell infusion occurs via a mechanism that is distinct from the mechanism of enhancement by donor bone marrow.  69:1020-1022. 2000
  • Posttransplant lymphoproliferative disorder localized near the allograft in renal transplantation.  69:809-814. 2000
  • Hepatopulmonary syndrome and venous emboli causing intracerebral hemorrhages after liver transplantation: A case report.  68:1809-1811. 1999
  • Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: A phase II trial.  68:1526-1532. 1999
  • Cytomegalovirus infection and posttransplant lymphoproliferative disease in renal transplant recipients: Results of the U.S. multicenter FK506 kidney transplant study group.  68:1203-1205. 1999
  • Safety, tolerability and efficacy of cyclosporine microemulsion in heart transplant recipients: A randomized, multicenter, double-blind comparison with the oil based formulation of cyclosporine - Results at six months after transplantation.  68:663-671. 1999
  • Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection.  68:310-313. 1999
  • Tolerability and side effects of anti-CD3-immunotoxin in preclinical testing in kidney and pancreatic islet transplant recipients.  68:215-219. 1999
  • Screening by tRNA primer extension analysis of porcine kidney mRNA libraries defines a novel endogenous porcine retroviral long terminal repeat.  67:1391-1395. 1999
  • Immunoregulatory role of CD8alpha in the veto effect..  67:372-380. 1999
  • Immunoregulatory role of CD8α in the veto effect: Transforming growth factor-b1 activation.  67:372-380. 1999
  • Recurrent primary sclerosing cholangitis after orthotopic liver transplantation: Is chronic rejection part of the disease process?.  66:1300-1306. 1998
  • PRIMARY NONFUNCTION: IS IT DUE TO IMPAIRED MITOCHONDRIAL AT SYNTHESIS?.  66:S8-S8. 1998
  • A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients.  66:507-515. 1998
  • Results of the double-blind, randomized, multicenter, phase III clinical trial of thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation.  66:29-37. 1998
  • Peritransplant tolerance induction with anti-CD3 immunotoxin: A matter of proinflammatory cytokine control.  65:1159-1169. 1998
  • Long-term outcome of patients transplanted with livers from hepatitis C- positive donors.  65:925-929. 1998
  • Commentary on a comparison of tacrolimus and cyclosporine for immunosuppression after cadaveric renal transplantation (multiple letters).  65:142-145. 1998
  • Mycophenolate mofetil for the treatment of a first acute renal allograft rejection.  65:235-241. 1998
  • Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation.  65:180-187. 1998
  • Protective effect of reduced glutathione on endothelial function of coronary arteries subjected to prolonged cold storage.  64:660-663. 1997
  • A molecular epidemiological probe for pig microchimerism.  64:347-350. 1997
  • Split tolerance induced by immunotoxin in a rhesus kidney allograft model.  63:1339-1345. 1997
  • A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation.  63:977-983. 1997
  • Immunolocalization of acidic fibroblast growth factor and receptors in the tubulointerstitial compartment of chronically rejected human renal allografts.  63:988-995. 1997
  • FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts.  63:1-6. 1997
  • A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection.  62:594-599. 1996
  • Immunolocalization of FGF-1 and receptors in human renal allograft vasculopathy associated with chronic rejection.  62:467-475. 1996
  • Immunolocalization of FGF-1 and receptors in glomerular lesions associated with chronic human renal allograft rejection.  62:190-200. 1996
  • Immunosuppressive effects of an HLA class I-derived peptide in a rat cardiac allograft model.  61:1222-1228. 1996
  • Molecular conjugate-mediated gene transfer into isolated human kidneys.  61:812-817. 1996
  • Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection.  61:722-729. 1996
  • Pentoxifylline does not prevent the cytokine-induced first dose reaction following OKT3 - A randomized, double-blind placebo-controlled study.  61:573-577. 1996
  • Impact of donor/recipient size matching on outcomes in renal transplantation.  61:383-388. 1996
  • Gas-generating systems in acute renal allograft rejection in the rat: Co-induction of heme oxygenase and nitric oxide synthase.  61:93-98. 1996
  • Pretransplant status and patient survival following liver transplantation.  60:920-925. 1995
  • Evaluation of living renal donors: The current practice of US transplant centers.  60:322-327. 1995
  • Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients.  60:225-232. 1995
  • Risk factors affecting second renal transplant outcome, with special reference to primary allograft nephrectomy.  60:138-144. 1995
  • A rapid flow cytometry assay for hla antibody detection using a pooled cell panel covering 14 serological crossreacting groups.  59:626-630. 1995
  • The predictive value of hepatocyte glycogen content on liver allograft biopsy: Correlation with early graft function.  59:141-143. 1995
  • Direct assessment of the antioxidant effects of a new heart preservation solution, celsior: A hemodynamic and electron spin resonance study.  58:739-742. 1994
  • Renal retransplantation: The role of race, quadruple immunosuppression, and the flow cytometry cross-match.  57:47-54. 1994
  • The incidence of subsequent acute rejection following the treatment of refractory renal allograft rejection with mycophenolate mofetil (RS61443).  57:640-643. 1994
  • Immunosuppressive therapy as a determinant of transplantation outcomes.  55:1297-1305. 1993
  • OKT3 rescue for steroid-resistant rejection in adult liver transplantation.  55:87-91. 1993
  • Regulation of cytokine-stimulated vascular cell adhesion molecule-1 expression in renal tubular epithelial cells.  55:172-177. 1993
  • Improved survival of primary cadaveric renal allografts in blacks with quadruple immunosuppression.  53:103-109. 1992
  • Proliferation of cytomegalovirus-primed lymphocytes in bronchoalveolar lavages from lung transplant patients.  54:635-639. 1992
  • Rs-61443—a phase i clinical trial and pilot rescue study.  53:428-432. 1992
  • The effect of erythropoietin and blood transfusions on highly sensitized patients on a single cadaver renal allograft waiting list.  53:363-368. 1992
  • The impact of the UNOS mandatory sharing policy on recipients of the black and white races-experience at a single renal transplant center.  53:770-774. 1992
  • Cytomegalovirus hemorrhoiditis in cardiac allograft recipients.  51:918-920. 1991
  • Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients.  51:70-75. 1991
  • Problems with therapeutic monitoring of cyclosporine using silicone central venous line samples.  52:1109-1110. 1991
  • Survival of ganciclovir-treated heart transplant recipients with cytomegalovirus pneumonitis.  52:910-913. 1991
  • Exquisite sensitivity of dendritic cells to ultraviolet radiation and temperature changes.  48:666-671. 1989
  • Functional and morphological studies of long-term islet allografts in the renal subcapsular space of the BB/W rat.  47:580-582. 1989
  • Successful renal allografts in recipients with crossmatch-positive, dithioerythritol-treated negative sera: Race, transplant history, and HLA-DR1 phenotype.  47:240-245. 1989
  • Use of cryopreserved donor bone marrow in cadaver kidney allograft recipients.  47:66-71. 1989
  • Donor-specific transfusions in renal transplantation in children effect of azathioprine plus transfusions.  44:159-161. 1987
  • Effect of low-temperature culture and site of transplantation on hamster islet xenograft survival (Hamster to mouse).  44:465-468. 1987
  • Primary integumentary allograft reactivity in the American cockroach, periplaneta Americana.  43:514-519. 1987
  • Lethal Graft-Vkrsus-Host disease in a recipient of a pancreas-spleen transplant.  41:544-546. 1986
  • Prolonged survival of donor skin grafts on mice bearing established islet of langerhans transplants.  40:216-218. 1985
  • Primary integumentary xenograft reactivity in the american cockroach, periplaneta Americana.  37:478-484. 1984
  • Reactivity of lymphocyte cytotoxic autoantibodies from renal patients with cell line K562.  38:557-558. 1984
  • Possibility of graft-vs-leukemia determinants independent of the major histocompatibility complex in allogeneic marrow transplantation.  35:378-385. 1983
  • Successful renal transplantation despite warm B cell antibodies.  36:207-209. 1983
  • Qa-1-associated antigens: IV. Evidence for additional Qa-1 polymorphism defined biochemically and by cytotoxic T lymphocyte recognition.  34:54-59. 1982
  • Fatal response suggestive of graft-versus-host reaction following transplantation of spleen cells from allogeneic athymic (Nude) donors.  31:201-204. 1981
  • Improved renal function using adenosine triphosphate-magnesium chloride in preservation of canine kidneys subjected to warm ischemia.  31:187-189. 1981
  • Exponential relationship between spleen cell concentration and fatal graft-versus-host response after transplantation of allogeneic spleen-marrow cell mixtures.  29:507-510. 1980
  • Percutaneous transluminal dilation in renal transplant arterial stenosis.  30:440-444. 1980
  • Effect of primary and recurrent cytomegalovirus infections upon graft and patient survival after renal transplantation..  28:443-446. 1979
  • Effect of primary and recurrent cytomegalovirus infections upon graft and patient survival after renal transplantation.  27:443-450. 1979
  • Ia and H-2 antigens on blast cells.  19:528-530. 1975
  • International Standard Serial Number (issn)

  • 0041-1337
  • Electronic International Standard Serial Number (eissn)

  • 1534-6080